Table 2.
Other adjunctive treatments used in patients treated with or without IVIgG
| Before propensity score matching | After propensity score matching | |||||
|---|---|---|---|---|---|---|
| IVIgG(+) (n = 960) |
IVIgG(–) (n = 2158) |
p value | IVIgG(+) (n = 653) |
IVIgG(–) (n = 653) |
p value | |
| Adjunctive treatments of sepsis (%) | ||||||
| Anti-DIC therapy | ||||||
| Antithrombin | 530 (55.2) | 439 (20.3) | <0.001 | 337 (51.6) | 188 (28.8) | <0.001 |
| Recombinant human soluble thrombomodulin | 431 (50.7) | 419 (19.4) | <0.001 | 270 (41.3) | 170 (26.0) | <0.001 |
| Heparinoid | 66 (6.9) | 93 (4.3) | 0.002 | 44 (6.7) | 35 (5.4) | 0.296 |
| Protease inhibitor | 195 (20.3) | 192 (8.9) | <0.001 | 129 (19.8) | 92 (14.1) | 0.006 |
| Low-dose steroid | 364 (37.9) | 399 (18.5) | <0.001 | 242 (37.1) | 147 (22.5) | <0.001 |
| Renal replacement therapy | 377 (39.3) | 501 (23.2) | <0.001 | 234 (35.8) | 165 (25.3) | <0.001 |
| Renal replacement therapy for non-renal indications | 135 (14.1) | 129 (6.0) | <0.001 | 88 (13.5) | 63 (9.6) | 0.031 |
| Polymyxin B direct hemoperfusion | 327 (34.1) | 357 (16.5) | <0.001 | 207 (31.7) | 142 (21.7) | <0.001 |
| Plasma exchange | 17 (1.8) | 12 (0.6) | 0.002 | 11 (1.7) | 5 (0.8) | 0.131 |
| Veno-arterial ECMO | 7 (0.7) | 21 (1.0) | 0.330 | 6 (0.9) | 4 (0.6) | 0.525 |
| Veno-venous ECMO | 14 (1.5) | 26 (1.2) | 0.335 | 7 (1.1) | 5 (0.8) | 0.562 |
| Intra-aortic balloon pumping | 5 (0.5) | 8 (0.4) | 0.369 | 3 (0.5) | 0 (0.0) | 0.083 |
| Transfusion (units) | ||||||
| RBC concentration | 2 (0–6) | 0 (0–4) | <0.001 | 2 (0–6) | 0 (0–4) | <0.001 |
| FFP | 0 (0–10) | 0 (0–0) | <0.001 | 0 (0–10) | 0 (0–4) | <0.001 |
| Platelet concentration | 0 (0–20) | 0 (0–0) | <0.001 | 0 (0–10) | 0 (0–0) | 0.002 |
DIC disseminated intravascular coagulation, FFP fresh frozen plasma, ECMO extracorporeal membrane oxygenation, RBC red blood cell